Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

[News]

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

More... (http://www.news-medical.net/news/20101217/Genentech-confirms-EMA-FDA-updates-on-Avastin-for-metastatic-breast-cancer.aspx)